Effectiveness or Orthopedic Intervention in Osteoporosis Management After a Fracture of the Hip With Cost-Benefit Analysis

Sponsor
Shaare Zedek Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT02239523
Collaborator
(none)
200
1
2
24.2
8.3

Study Details

Study Description

Brief Summary

Patients who present with fragility fractures are consistently under-evaluated and under-treated for underlying osteoporosis. This point of care represents a lost opportunity to prevent future fractures. The medical field treats the fracture as if the fall is the problem, but bone quality is the real problem. Studies have consistently shown that the recommendations of the International Osteoporosis Foundation and World Health Organization are not being followed. Orthopedics treats the patients for their fractures and primary care physicians focus on general health but no one is taking responsibility for bone health. Strategies to convince primary care to assume care have not succeeded. On the other hand, strategies where orthopedics takes some responsibility have shown success. This prospective 2-arm study will evaluate the success of effort by an academic orthopedic department in osteoporosis evaluation and treatment. We hypothesize that with greater effort by the orthopedic department, the better the adherence to standards of care. A cost benefit analysis will be made in parallel.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Letter Group
  • Procedure: Intervention Group
N/A

Detailed Description

Patients who present to the orthopedic department in a level I trauma center will be prospectively randomized into one of two groups:

Letter Group: At time of discharge, patients will be sent home with a discharge letter that includes standard recommendations for evaluation and treatment. They will be asked to give the letter to their primary care physician.

Intervention Group: There will be 4 interventions. The patient will be given a short pamphlet with explaining osteoporosis and the importance of treatment. The orthopedic department will perform a bone density testing (DEXA). They will be given a letter with a specific medication recommendation based on a protocol determined by our endocrinology department. They will be asked to give both DEXA and medication recommendation to their primary care doctor to initiate treatment. Finally, a research assistant will contact the patient monthly to encourage them to start treatment.

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Management Strategies by an Orthopedic Department to Improve the Evaluation and Treatment of Osteoporosis.
Actual Study Start Date :
Feb 21, 2017
Actual Primary Completion Date :
Jan 17, 2019
Actual Study Completion Date :
Feb 28, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Letter Group

Patients will be given discharge letter that includes recommendation to discuss further testing and treatment with their primary care physician.

Procedure: Letter Group
At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.

Experimental: Intervention Group

Patients will be given a pamphlet about osteoporosis and importance of treatment, have a bone density test (DEXA) arranged, be given a specific medication recommendation and monthly followup phone calls.

Procedure: Intervention Group
The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
Other Names:
  • Intervention
  • Dual-energy X-ray absorptiometry
  • Bone density scan
  • Bisphosphonate
  • Prolia
  • Denosumab
  • Forteo
  • Teriparatide
  • Outcome Measures

    Primary Outcome Measures

    1. Percentage of patients with osteoporosis that are appropriately treated [Determination of proper treatment will be made at 4 months after the fracture.]

      Treatment will be determined based on a pre-determined algorithm by our endocrinology department. This will be based on patient factors and results of DEXA is not part of the algorithm. All patients with a fragility fracture of the hip, regardless of DEXA results will be considered for treatment.

    Secondary Outcome Measures

    1. Percentage of patients who undergo DEXA scan. [Evaluation will be made 4 months after the initial fracture event.]

      Whether or not the patients received the medication

    Other Outcome Measures

    1. Cost benefit analysis [Evaluation will be made at time of discharge and up to 4 months from the fracture event.]

      Cost analysis will be made for each patient during the hospitalization and for 3 months after the fracture to capture complications related to the initial event.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years to 120 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All patients over age 50 with fragility fracture defined as a fall from standing or walking position
    Exclusion Criteria:
    • Patients with metastatic cancer

    • Known metabolic bone disease

    • End-of-life care

    • Inability to provide consent

    • Known MRSA carriers

    • Fractures of the trochanter alone, shaft or peri-prosthetic fractures

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Shaare Zedek Medical Center Jerusalem Israel 91031

    Sponsors and Collaborators

    • Shaare Zedek Medical Center

    Investigators

    • Principal Investigator: Gershon Zinger, MD MS, Shaare Zedek Medical Center, Jerusalem Israel

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Shaare Zedek Medical Center
    ClinicalTrials.gov Identifier:
    NCT02239523
    Other Study ID Numbers:
    • 201497CTIL
    First Posted:
    Sep 12, 2014
    Last Update Posted:
    Apr 5, 2019
    Last Verified:
    Sep 1, 2018
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Shaare Zedek Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 5, 2019